Partner Headlines - BIIB

  1. Ken Fisher's Top Increaes of the Second Quarter

    GuruFocus
  2. Ken Fisher's Top Increases of the Second Quarter

    GuruFocus
  3. Chipotle, Facebook Rally On Upside Earnings Surprise

    IBD
  4. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD
  5. Celgene, Alexion Earnings Top Street, But Stocks Fall

    IBD
  6. Biogen, Gilead Profits Soar

    IBD
  7. Biogen, Gilead Crush Earnings Estimates On Hot Drugs

    IBD
  8. S&P 500 Posts New High; Biotechs, Airlines, Builders Up

    IBD
  9. IPO Stock Watch: Biotechs Are Half Of July Calendar

    IBD
  10. Vertex Is Poised For An Earnings Breakout

    Benzinga
  11. Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential ...

    Benzinga
  12. S&P 500 Flirts With High; Breadth Missing On Nasdaq

    IBD
  13. Intuitive Surgical Rises On Upbeat Earnings; Xilinx Shares Slip

    Benzinga
  14. S&P 500 Aims At New High; Biotechs Gap Up In Fast Trade

    IBD
  15. Biogen Trounces Q2 Estimates As Tecfidera Outperforms

    IBD
  16. Apple, Microsoft Lead Nasdaq Higher; Dow Falters

    IBD
  17. Markets Mixed; PepsiCo Q2 Earnings Beat Street View

    Benzinga
  18. Stocks: Mixed Open, Mixed Trade; Delta, Broadcom, Biogen Buck ...

    IBD
  19. Morning Market Movers

    Benzinga
  20. UPDATE: Biogen Idec Posts Stronger-Than-Expected Q2 Results, ...

    Benzinga
  21. Stock Futures Up, But Wobbly; Boeing, Apple, Biogen Rising

    IBD
  22. Benzinga's Top #PreMarket Gainers

    Benzinga
  23. Earnings Scheduled For July 23, 2014

    Benzinga
  24. Stocks Rise; Apple, Microsoft Steady In Post-Session

    IBD
  25. Alexion, 3 Other Top Biotechs Reporting Earnings

    IBD
  26. Stocks Climb In Solid Trade; Chipotle Gaps Up, Breaks Out

    IBD
  27. Oil Dominates; Keurig, Constellation Near Buy Points

    IBD
  28. IBD 50 Ends Week Lower But Skyworks Soars

    IBD
  29. Biogen Shares Rebound As Street Has A Change Of Heart

    IBD
  30. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  31. IBD 50 Ends Week Lower But Skyworks Soars

    IBD
  32. Biotech Enters Reporting Season With Large Caps Central To Sector ...

    Benzinga
  33. Baxter Q2 Earnings Beat Estimates, But Guidance Soft

    IBD
  34. IBD Big Cap 20 Leaders Hold Up Well Despite Shaky Market

    IBD
  35. Biogen's Profit Rolls Amid Recent Drug Launches

    IBD
  36. Stocks Close Higher As Biotech, Internet Stocks Gain

    IBD
  37. Deutsche Bank Analyst Talks Up Biogen On CNBC; Stock Responds ...

    Benzinga
  38. Alexion Pharma Looks To Life Beyond Its Blockbuster

    IBD
  39. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  40. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  41. Top 4 Stocks In The Biotechnology Industry With The Highest EPS

    Benzinga
  42. AbbVie, Shire Give Bullish Guidance Amid Buyout Talk

    IBD
  43. ISIS Pharma Trades Up Premarket; NYT Says Has Potential Heart ...

    Benzinga
  44. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  45. Biogen, AbbVie Report Positive Top-Line Results from Phase 3 ...

    Benzinga
  46. 50-Day Moving Average Can Buffer A Strong Stock's Advance

    IBD
  47. UPDATE: Morgan Stanley Reiterates On Biogen Idec As Positive ...

    Benzinga
  48. Stock Indexes Slightly Up; Apple Split Takes Effect

    IBD
  49. UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Good ...

    Benzinga
  50. US Stock Futures Slightly Lower Ahead Of McDonald's Sales Report

    Benzinga
  51. ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica ...

    Benzinga
  52. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest ...

    Benzinga
  53. Investor's Corner: How To Use The Big Cap 20

    IBD
  54. Walgreen Shares Climb Sharply in Holiday-Lifted April

    IBD
  55. Walgreen Hits Record Close On Sweet Easter Sales

    IBD
  56. Biogen to Present Plegridy Data from Phase 3 Study at AAN Annual ...

    Benzinga
  57. Market Wrap For April 28: Apple Hits New 52-Week Highs In a Volatile ...

    Benzinga
  58. Amgen Blazed Biotech Trail, Earned 165,233% Reward

    IBD
  59. Market Wrap For April 24: Apple's Smashing Earnings Overshadowed ...

    Benzinga
  60. Biogen EPS misses, guides up

    IBD
  61. Biogen Q1, Guidance Strong, But Stock Slips

    IBD
  62. Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple ...

    Benzinga
  63. Biogen Q1 Sales Beat Street, Guidance Strong

    IBD
  64. Earnings Scheduled For April 23, 2014

    Benzinga
  65. Ken Fisher's Top Increases of the First Quarter

    GuruFocus
  66. A Drill Can Help Identify Right Time To Sell Leaders

    IBD
  67. Stocks Rise In Higher Volume; Gilead Up After Hours

    IBD
  68. Johnson & Johnson: Why Top Funds Are Buying

    YCharts
  69. Biogen Idec Signs License Agreement With Amunix for XTENylated ...

    Benzinga
  70. Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings

    IBD
  71. Stocks: Thin Gains; Yellen Coaxes Banks To Fortify

    IBD
  72. Biogen to Present Clinical Data from Neurology Portfolio at AAN ...

    Benzinga
  73. IPO Frenzy Freezes As 4 New Issues Delayed

    IBD
  74. Stocks Hit Again; Nasdaq Ends Below 4000

    IBD
  75. Hemophilia drug draws plaudits

    IBD
  76. Market Wrap For April 10: Wednesday's Rally Completely Forgotten

    Benzinga
  77. Biotech IPOs Adamas, Cerulean Slump In Trading Debut

    IBD
  78. Software, Biotech, Solar Names Weigh on Nasdaq

    IBD
  79. Sellers Dictate Action As Growth Stocks Tumble Again

    IBD
  80. Stocks Fall Hard In Early Trade; Biotechs Take Heat Again

    IBD
  81. Stocks Mixed, Volume Mixed; HP, IBM, AT&T Rise

    IBD
  82. Nasdaq Up 1.7%; Bed, Bath & Beyond Sinks After Hours

    IBD
  83. Stocks Extend Gains; Trimble Navigation Finds Support

    IBD
  84. Alexion, Biogen Among Leading Big-Cap Biotechs

    IBD
  85. Don't Panic Over Recent Tech Turmoil

    FoxBusiness
  86. Stocks Rally, Stall, Turn Mixed; Consol Energy, U.S. Steel Jump

    IBD
  87. Biotechs Struggling To Find A Bottom

    Benzinga
  88. Biogen Idec May Have Seeds For Next-Gen MS Drugs

    IBD
  89. Stocks Weaken In Late Trade; Questcor Pares Gains

    IBD
  90. Major Averages Face More Selling, Biotechs Rally Back

    IBD
  91. IBD 50 Stocks Fade With Market; Some Trip Sell Rules

    IBD
  92. Stocks Fall Ahead Of Jobs Data; Palo Alto, Tableau Slide

    IBD
  93. Nasdaq Sheds 1% As China Growth Names, Biotechs Fall Hard

    IBD
  94. S&P 500 Edges Lower As Biotech Selling Weighs On Nasdaq

    IBD
  95. Nasdaq Leads Another Up Day; S&P 500 Hits All-Time High

    IBD
  96. Trial Results Lift Drug Sector

    IBD
  97. Stocks Hold Gains After Yellen Comments; Biotechs Bounce

    IBD
  98. Gilead Adds To Biotech Woes

    IBD
  99. Gains Fade Into Quiet Finish

    IBD
  100. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
Trading Center